Literature DB >> 16785454

Microvascular dysfunction in cardiac syndrome X: the role of inflammation.

Ramón Arroyo-Espliguero1, Juan Carlos Kaski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16785454      PMCID： PMC1475907          DOI： 10.1503/cmaj.051331

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X.

Authors:  Pier Giorgio Masci; Martin Laclaustra; Juan Garcia Lara; Juan Carlos Kaski
Journal:  Am J Cardiol       Date:  2005-06-15       Impact factor: 2.778

Review 2.  Cardiac syndrome X. Diagnosis, pathogenesis and management.

Authors:  Juan Carlos Kaski; Guillermo Aldama; Juan Cosín-Sales
Journal:  Am J Cardiovasc Drugs       Date:  2004       Impact factor: 3.571

3.  C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms.

Authors:  Juan Cosín-Sales; Carmine Pizzi; Sue Brown; Juan Carlos Kaski
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

4.  Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X.

Authors:  Ramón Arroyo-Espliguero; Nadia Mollichelli; Pablo Avanzas; Emmanouil Zouridakis; Valentine R Newey; Dariush K Nassiri; Juan Carlos Kaski
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

5.  Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study.

Authors:  J C Kaski; G M Rosano; P Collins; P Nihoyannopoulos; A Maseri; P A Poole-Wilson
Journal:  J Am Coll Cardiol       Date:  1995-03-15       Impact factor: 24.094
  5 in total
  10 in total

1.  Vascular inflammation.

Authors:  Ettore Corsi
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

2.  Vascular inflammation.

Authors:  Craig S McLachlan
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

3.  Lipid Profile in Cardiac Syndrome X: Association with Helicobacter pylori.

Authors:  Yousef Rasmi; Javad Zeynalzadeh; Alireza Shirpoor; Mirhossein Seyedmohammadzad; Reza Hajhosseini
Journal:  J Clin Diagn Res       Date:  2016-07-01

4.  Receptor for advanced glycation end products gene polymorphisms in cardiac syndrome X.

Authors:  Burak Önal; Deniz Özen; Bülent Demir; Ahmet G Akkan; Sibel Özyazgan
Journal:  Biomed Rep       Date:  2019-07-22

Review 5.  The relationship between retinal microvascular abnormalities and coronary heart disease: a review.

Authors:  Benjamin R McClintic; Jedediah I McClintic; John D Bisognano; Robert C Block
Journal:  Am J Med       Date:  2010-04       Impact factor: 4.965

6.  Investigation of MTHFR gene C677T polymorphism in cardiac syndrome X patients.

Authors:  Cemre Kandaz; Burak Önal; Deniz Özen; Bülent Demir; A Gökhan Akkan; Sibel Özyazgan
Journal:  J Clin Lab Anal       Date:  2017-05-08       Impact factor: 2.352

Review 7.  Contemporary treatment of Western and Chinese medicine for cardiac syndrome X.

Authors:  Ying-Fei Bi; Jing-Yuan Mao; Xian-Liang Wang; Heng-He Wang; Yong-Bin Ge; Zhen-Peng Zhang
Journal:  Chin J Integr Med       Date:  2011-04-21       Impact factor: 1.978

8.  Association of endothelial dysfunction and cytotoxin-associated gene A-positive Helicobacter pylori in patients with cardiac syndrome X.

Authors:  Yousef Rasmi; Hadi Rouhrazi; Ebrahim Khayati-Shal; Alireza Shirpoor; Ehsan Saboory
Journal:  Biomed J       Date:  2016-11-07       Impact factor: 4.910

9.  Increased levels of angiogenic factors in microvascular angina.

Authors:  Elmira Roshani Asl; Yousef Rasmi; Mohammad-Hasan Khadem-Ansari; MirHossein Seyed-Mohammadzad; Alireza Rostamzadeh; Fereshteh Ghaffari; Narmin Mokarizadeh
Journal:  Med Pharm Rep       Date:  2019-01-15

Review 10.  Traditional chinese medicine in coronary microvascular disease.

Authors:  Zhihua Yang; Shanshan Lin; Yangxi Liu; Qiuan Ren; Zhao Ge; Ci Wang; Yingfei Bi; Xianliang Wang; Jingyuan Mao
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.